About this trial
This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Patient Profile
To be eligible for this study, patients must meet several requirements, including:
- Participants must have inoperable or metastatic chondrosarcoma that is continuing to grow.
- At least 4 weeks must pass between the completion of any prior treatments and receipt of the study medication.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
Where’s this trial being run?
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | INBRX-109 |
|---|---|
| Number: | 24-33 |
| Full Title: | A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma |
| Principal Investigator: | |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Inhibrx Biosciences, Inc |
| Recruitment Started: |
Global: 23-09-2021 Ireland: |
| Global Recruitment Target: | 201 |
|---|---|
| Ireland Recruitment Target: |